BPC-157 and the evidence gap: what 30 years of pre-clinical data does — and doesn’t — tell us
A structured review of the BPC-157 evidence record, from repeated pre-clinical findings to the absence of a robust human clinical evidence base.
What BPC-157 is, and where it comes from
BPC-157 — Body Protection Compound 157 — is a synthetic pentadecapeptide (15 amino acids) derived from a sequence within the gastric protein BPC. It was first identified and isolated by a research group at the University of Zagreb in the 1990s, primarily in the context of gastric protection and ulcer healing. The original hypothesis was that the gastric mucosa contains a naturally occurring compound that protects the stomach lining — BPC-157 is a stabilised, synthetic fragment of that endogenous sequence.
Over the subsequent three decades, a significant body of research has accumulated — almost entirely in animal models, predominantly in rats. The breadth of that research is unusual. BPC-157 has been studied not just in the GI context where it originated, but across tendon repair, ligament healing, wound closure, neurological models, cardiovascular function, and systemic inflammation. This breadth of pre-clinical interest is part of what makes it one of the more discussed compounds in research circles — and one of the more commercially prominent in the RUO market.
“The volume of pre-clinical data on BPC-157 is not in question. What is in question is what that data licenses us to say — and what it doesn’t.”
The pre-clinical evidence base
The published animal study literature on BPC-157 is substantial. A 2021 review identified over 100 peer-reviewed publications examining the compound across multiple biological systems. In connective tissue repair models, BPC-157 has consistently shown effects on tendon-to-bone healing, ligament regeneration, and the rate of wound closure. In GI models, the protective and healing effects on gastric mucosa, colonic anastomosis, and intestinal fistulae have been replicated across multiple independent research groups.
Neurological studies — largely conducted in rat models of depression, traumatic brain injury, and spinal cord damage — have shown significant effects on locomotor recovery and neuroprotection markers. Cardiovascular work has suggested effects on blood vessel formation and endothelial nitric oxide synthase activity. The proposed mechanism across many of these effects centres on the FAK-paxillin pathway and, more broadly, on the regulation of growth factor expression including VEGF and EGF receptor signalling.1
This is a wide footprint for a single 15-amino-acid compound. The consistent finding across the literature — that BPC-157 appears to modulate repair and protective processes across multiple tissue types — is what has attracted continued research interest. It is also, notably, what should prompt the most careful reading of the evidence.
No published human trial data exists as of the date of this report. All effects referenced here are derived from in-vitro cell studies or animal model research.
The human data gap
Here is the central issue: despite 30 years of active pre-clinical research and a significant commercial market for BPC-157 as a research compound, there are — as of this writing — no published, peer-reviewed, randomised controlled trials of BPC-157 in human subjects for any indication.
There are anecdotal reports. There are forums. There is a great deal of inference from animal data. There is one ongoing registered trial (NCT04197775, examining BPC-157 in inflammatory bowel disease) which had not published results as of publication of this report. But the peer-reviewed human evidence base is, at this point, absent.
This does not mean that the pre-clinical findings are wrong, or that human effects are impossible to project from them. It means that the translation from animal model to human biology — which is never guaranteed and has failed for a significant proportion of compounds with strong pre-clinical profiles — has not been tested. The mechanisms proposed for BPC-157’s effects are biologically plausible. Plausibility is not the same as demonstrated efficacy in humans.2
“Plausibility is not the same as demonstrated efficacy. The history of pharmacology is full of compounds that were biologically plausible and did not survive clinical trials.”
What the research community does with this
The responsible approach to a compound in BPC-157’s position is to continue to monitor the pre-clinical literature, acknowledge that the evidence base is genuinely interesting, and wait for human trial data before drawing conclusions about efficacy in people. The Index does not take a position on whether BPC-157 will or will not show the effects observed in animal models when studied in humans. We don’t know — and neither does the published literature.
What we do note in the Index entry is that the open questions are significant: optimal delivery route in humans is unstudied; bioavailability data from human pharmacokinetic studies is absent; dose-response relationships established in rats may not translate; and the mechanism, while biologically coherent, has not been validated in human tissue.
Open questions remaining
The entry for BPC-157 in the Index carries four documented open questions: human pharmacokinetics, optimal delivery route and dose, interaction with existing conditions or medications at a systemic level, and long-term safety profile. These are not small uncertainties. They are the foundational questions that any human trial would need to address.
The compound remains one of the most actively discussed in the pre-clinical peptide research space, and the Index will update this entry as published evidence develops. If the ongoing IBD trial publishes results, this will represent the first peer-reviewed human data on BPC-157 and will substantially change the evidence picture.
Key references
- Sikiric P, et al. (2021). Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Current Neuropharmacology, 19(1), 1–25.
- Chang CH, et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3), 774–780.
- Gwyer D, Wragg NM, Wilson SL. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(2), 153–159.